Merck Stock News

Here are 3 Dow Jones stocks to watch in the stock market today.

After a forgettable last year, Merck & Co., Inc.'s stock price is up 20% YTD, supported by approvals, a positive outlook for 2024, and an attractive forward P/E. Keytruda, the company's top-selling tr

Given its attractive valuation, we believe Pfizer stock (NYSE: PFE) is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

As the number of grey-haired people rises worldwide, investors need to notice the strong-buy  healthcare stocks. The need for healthcare will grow as the number of people aged 60 years and older dou

Merck (MRK) reachead $131.95 at the closing of the latest trading day, reflecting a +0.15% change compared to its last close.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Jerry Castellini, Castle Ark Management president and CIO, joins 'Power Lunch' to discuss Castellini's investing take on three stocks: Tesla, Merck, and RH.

Merck & Co Inc (NYSE:MRK, ETR:6MK) shares traded more than 4% higher after it won US Food and Drug Administration (FDA) approval for its lung disorder drug sotatercept, brand name WINREVAIR.  After b

Merck & Co Inc  (NYSE:MRK) was last seen up 4.4% to trade at $130.99, after the Food and Drug Administration (FDA) approved its Winrevair treatment for adults with high blood pressure due to constri

Zacks.com users have recently been watching Merck & Co. (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.

Merck shares gain 5% to $131.90 in afterhours trading following approval of its new drug for a potentially fatal lung disease.

The approval is a win for Merck, which is working to diversify its revenue stream as its blockbuster cancer drug Keytruda nears a loss of market exclusivity.

The U.S. FDA on Tuesday approved Merck's treatment for adults with high blood pressure due to constriction of lung arteries, adding another potential blockbuster drug to the pharmaceutical giant's por